Dietary Supplement Listing Act of 2026
The Dietary Supplement Listing Act of 2026 would amend the Federal Food, Drug, and Cosmetic Act to create a federal listing requirement for dietary supplements marketed in the United States. Manufacturers, packers, distributors, or their U.S. agents would have to submit detailed product information to the Food and Drug Administration, including product names, responsible-party contact information, labels, ingredient lists, serving information, directions for use, warnings, allergen statements, product form, and certain label claims. The bill also requires updates when products change, notice when products are discontinued, and prompt responses to FDA requests for additional facility and sourcing information.
The bill directs FDA to assign each listed supplement a product listing number and to establish a publicly searchable electronic database within two years of enactment. Some information would be publicly available, while sensitive data such as certain contact details, proprietary blend quantities, and facility-identifying information would be withheld from public disclosure. The bill also sets different compliance timelines for supplements already on the market versus new supplements introduced after January 1, 2027, and it authorizes appropriations to carry out the new program.
If enacted, the bill would add a new section 403D to the Federal Food, Drug, and Cosmetic Act and create a new misbranding provision for dietary supplements that fail to comply with listing, update, or information-submission requirements. It would expand FDA oversight of the dietary supplement market by requiring a centralized product registry and public database, while preserving the agency’s existing authority to inspect records and without creating premarket approval authority. The measure would directly affect supplement manufacturers, packers, distributors, foreign entities with U.S. agents, and retailers relying on compliant labeling and product identification.
The available record shows no committee transcript, recorded votes, or formal amendments, so there is no documented floor or committee debate to gauge broad sentiment. Based on the bill’s structure, the measure appears oriented toward transparency, consumer information, and FDA enforcement, suggesting a generally regulatory and public-health-focused intent. Because it was only referred to the House Committee on Energy and Commerce, the bill appears to be in an early stage with no visible vote history in the provided materials.
The main likely points of contention are the compliance burden on supplement companies, the scope of information that must be submitted to FDA, and the creation of a public database for product information. Industry stakeholders may object to the administrative costs, the need to update listings for product changes, and the potential exposure of sensitive business information, especially for proprietary blends and foreign-manufactured products. Supporters would likely emphasize consumer transparency, better traceability, and improved FDA oversight, while the bill itself tries to balance those concerns by withholding certain confidential data and explicitly stating that it does not authorize premarket approval.